To Describe the Clinical, Endoscopic and Endoscopic Ultrasound Features of Non-bleeding and Bleeding Rectal Varices, Among Patients With Portal Hypertension
NCT ID: NCT04535440
Last Updated: 2021-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-01-07
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis
NCT04932200
Upper Endoscopy in Cirrhotic Patients With Upper Gastrointestinal Bleeding
NCT06214234
Timing of Endoscopy in Cirrhotic Patients with Acute Variceal Bleeding
NCT06031402
Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound
NCT07051369
EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.
NCT05597488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To describe the clinical, radiological, endoscopic and endoscopic-ultrasound features of non-bleeding and bleeding rectal varices, among patients with portal hypertension.
OBJECTIVES:
Primary objectives:
Anatomical and liver -related risk-factors for presence of rectal varices (RV) among patients with portal hypertension Secondary objectives
1. Etiological spectrum of bleeding per-rectum, among patients with PHT.
2. Frequency of coexistence of hemorrhoids with RV.
3. Distribution and size of variceal channels in the rectum on endoscopy and endoscopic ultrasound (EUS).
4. Location and numbers of inflow and outflow perforator channels for RV on endoscopic ultrasound (EUS).
Patients and methodology
Study Population:
All patients with PHT (cirrhotic or non-cirrhotic), with active or prior anorectal bleeding (defined later) in the preceding 6-months will be evaluated for inclusion. We will also include patients with incidental detection of RV during endoscopy done for other indications. We will include both indoor and outdoor patients, attending the Department of Hepatology, ILBS, New Delhi. An informed consent will be obtained from the participants in the study.
Study Design Cross- sectional, observational and descriptive study
Study period September 2020 to February 2020. Baseline data
The following clinical, biochemical and radiological features will be recorded (detailed in the proforma):
1. Liver disease etiology and severity, including Fibroscan and HVPG, where done.
2. Upper endoscopy findings.
3. Details of prior bleeding episodes if any (upper and lower).
4. Details of current bleeding episodes.
5. Radiological features (cirrhosis, splanchnic venous thrombosis, flow direction in portal vein (PV) and its tributaries, inferior mesenteric vein (IMV) diameter, enlarged para-rectal collateral circulation, large porto-systemic shunts).
Endoscopy protocol:
All patients will undergo a sigmoidoscopy or colonoscopy procedure, as per the clinical indication. Patients found to have RV will undergo EUS examination in addition. EUS evaluation of patients with hemorrhoids alone will be done at the discretion of the examiner after informed consent from the patient.
Bowel preparation: Patient will be advised liquid-soft diet for 24 hours before the examination day. Split dose PEG preparation (2-4 L volume) will be administered- 2L in evening before and 2L on day of procedure till 4hours before the study scheduled time.
Patient position: Left lateral position. Endoscopes: Colonoscope or gastroscope. EUS probes: Radial and linear EUS scopes, paired with Olympus compact EUS processor EU-M2.
Operators: Procto-sigmoidoscopy: HS supervised by VB/ VB EUS: VB/ HS supervised by VB
Study Definitions:
Lower GI bleeding LGIB will be defined as bleeding from a source distal to the ileocecal valve (24).
Acute lower gastrointestinal bleeding Acute LGIB will be defined as bleeding of recent duration (\<3 days) that may result in hemodynamic instability, anemia, and/or the need for blood transfusion (25).
Clinically significant lower gastrointestinal bleeding\[VB1\] Requirement for blood transfusion, a hemoglobin drop of \> 3g/dL from baseline or need for hospital admission.
A bleeding episode is clinically significant when there is (BAVENO III\[VB2\] ):
1\. Transfusion requirement of ≥ 2 units of blood within 24 hours of time zero, 2. Systolic blood pressure \< 100 mmHg or a postural change of \>20 mmHg, 3. Pulse rate \>100/min at time zero Anorectal bleeding
1. Anorectal bleeding will be defined as red bleed per-rectum without or with stool expulsion. In the latter instance it can be mixed with stools, may smear stool, may dribble after defecation, or may smear wipes.
2. Anorectal bleeding may be painless or may be associated with pain.
3. Anorectal bleeding may or may not be associated with hemodynamic changes.
Monitoring and assessment
Primary:
1\. Anatomical and liver -related risk-factors for presence of rectal varices (RV) among patients with portal hypertension
Secondary
1. Etiological spectrum of bleeding per-rectum, among patients with PHT.
2. Frequency of coexistence of hemorrhoids with RV.
3. Distribution and size of variceal channels in the rectum on endoscopy and endoscopic ultrasound (EUS).
4. Location and numbers of inflow and outflow perforator channels for RV on endoscopic ultrasound (EUS).
Statistical analysis The dependent variable in the study will be presence of RV, presence of large RV (\>5mm), and RV bleeding. Independent variables will be presence/ absence of esophageal varices, gastric varices, ectopic varices, prior UGIE bleeding, prior endotherapy for esophago-gastric varices, ascites, gastro-lieno-renal shunt, other large porto-systemic shunt, PV and/or SV and/or SMV thrombosis or flow reversal, composite liver function scores (CTP and MELD), number, location, and size of rectal perforator channels, size of para-rectal collaterals, pulsatile/ phasic flow in perforator(s) and/or RV, and presence of hemorrhoids. The continuous data will be represented by Mean ± SD or by Median (IQR) as appropriate. The categorical data will be represented as frequency (%). Student t-test or Mann Whitney test will be used for quantitative data and Chi square test will be used for qualitative data. Besides this an appropriate statistical analysis like uni-variate and multi-variate logistic regression will be used at the time of data analyss. The significance will be seen at 5 %.
Adverse Event:
1. Pain abdomen
2. Bloating sensation
3. Abdominal distension
Stopping Rule:No stopping rule
Ethical Issues in the study and plans to address these issues:No ethical issue related to my study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rectal varices with bleed
No intervention
No intervention
Rectal varices without bleed
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with PHT and active or prior anorectal bleeding in preceding 6-months.
3. Patients with RV (bleeding or non-bleeding) detected on LGI endoscopy.
4. Ability to understand study procedures, and to comply with them for the entire length of the study.
Exclusion Criteria
2. Proctitis- infective, inflammatory bowel disease (IBD), radiation, or unspecified.
3. Pregnant or lactating females.
4. Presence of hemodynamic instability.
5. Presence of encephalopathy
6. Non-consenting adult patient or guardian.
7. Prior history of banding or surgery for hemorrhoids, or endotherapy for RV.
8. Prior shunt occlusion procedures like BRTO or PARTO, or shunt creation procedures like TIPS.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-PHT-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.